METHODS:
We retrospectively evaluated data of 3 patients that received AAT as
second-line therapy for acute SR-GvHD. Patients had undergone allogeneic
HSCT from related or unrelated donors with reduced-intensity
conditioning regimens (RIC) and had developed acute GvHD unresponsive to
high dose steroids. Steroid refractoriness is defined as progression in
GvHD within 3–5 days of starting the treatment or an incomplete
response by 7–14 days. All patients’ GvHD status was classified by
Glucksberg criteria.11 Endoscopic and colonoscopic
examinations were performed and intestinal GvHD was proven by biopsies
for all patients. All patients had received multiple second-line
therapies before AAT administration.